Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
复制标题
DOI：
10.1086/595011
复制
发表时间：
2009-01-01
影响因子：
11.8
通讯作者：
Bartlett, John
中科院分区：
文献类型：
--
作者：
Boucher, Helen W.;Talbot, George H.;Bartlett, John
美国传染病协会（IDSA）继续关注用于治疗耐药性感染的新型治疗方法的贫乏管道，特别是由革兰氏阴性病原体引起的感染。现在发生的感染对目前所有的抗菌药物都有抗药性。尽管IDSA对目前处于临床前开发阶段的一些药物的成功前景感到鼓舞，但迫切需要对这些泛耐药生物体具有活性的新药物。没有证据表明，在可预见的将来，这一需求将得到满足。此外，我们仍然担心发现和开发新抗菌药物的基础设施继续停滞不前，从而危及未来抗菌药物的管道。IDSA在其2004年的政策报告中提出了解决方案，“Bad Bugs，No Drugs：As Antibiotic R&D Stagnates，a Public Health Crisis Brews”，最近发布了“Call to Action”，以提供有关问题范围和拟议解决方案的最新信息。这些定期报告的主要目的是鼓励社区和立法机构做出反应，在抗菌药物开发和其他药物开发之间建立更大的财政平衡。尽管美国食品和药物管理局和第110届美国国会最近的行动带来了一线希望，但仍存在重大的不确定性。现在，比以往任何时候都更有必要建立一个强大的和可持续的抗菌研究和开发基础设施，一个可以应对当前的抗菌药物耐药性，并预测不断演变的耐药性。这一挑战要求工业界、学术界、美国国立卫生研究院、食品和药物管理局、疾病控制和预防中心、美国国防部以及卫生与公众服务部新成立的生物医学高级研究与发展管理局开展富有成效的合作。本报告提供了在后期开发管道中潜在有效的抗菌药物的最新情况，希望鼓励这种合作行动。
The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report," Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews,"and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure-one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.